Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium (Nasdaq: EQ) presented three posters highlighting EQ504, their novel AhR agonist drug candidate, at IMMUNOLOGY2025. The presentations demonstrated EQ504's potential in treating ulcerative colitis through multiple mechanisms. The research showed that EQ504:
1) Promotes immune tolerance by enhancing Treg stability while suppressing inflammatory Th17 responses 2) Demonstrates superior potency compared to its parent compound ITE in inducing CYP1A1 activity and anti-inflammatory cytokines 3) Effectively reduces gut pathology in mouse models of ulcerative colitis 4) Preserves barrier function and promotes healing of intestinal epithelial cells through IL22RA and IL10 expression
According to CSO Dr. Stephen Connelly, these findings highlight EQ504's potential as a treatment for ulcerative colitis, where poor mucosal healing currently limits patient remission.
Equillium (Nasdaq: EQ) received feedback from the FDA regarding itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). The FDA declined to grant Breakthrough Therapy designation and did not support an Accelerated Approval pathway based on the EQUATOR study data.
The FDA emphasized the importance of Day 29 response outcomes but showed openness to evaluating other endpoints, including longer-term outcomes, if supported by independent data. In response, Equillium plans to accelerate the closure of the EQUATOR study.
The company reported cash and cash equivalents of $14.5 million as of March 31, 2025, which is expected to fund operations into the third quarter of 2025.
Equillium (Nasdaq: EQ) announced topline data from its Phase 3 EQUATOR study evaluating itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). While the study did not show improvement in complete response (CR) or overall response rate (ORR) at Day 29, it achieved statistical significance in key longer-term outcomes.
Key findings include:
- Duration of CR: 336 days vs. 72 days (p=0.017)
- Failure-free survival: 154 vs. 70 days (p=0.043)
- Complete response at Day 99: 44.9% vs. 28.6% (p=0.035)
- Positive trend in overall survival with mortality of 24.4% vs. 32.5%
Itolizumab demonstrated a favorable safety profile without increasing infection or sepsis risks. The company has submitted for Breakthrough Therapy designation and expects FDA feedback in May 2025. If positive, they plan to submit a biologics license application in H1 2026.
Equillium (Nasdaq: EQ) announced topline data from its Phase 3 EQUATOR study evaluating itolizumab for first-line acute graft-versus-host disease (aGVHD). While the study missed its primary endpoint of Day 29 complete response, it showed significant longer-term benefits including:
- Duration of complete response: 336 days vs. 72 days (p=0.017)
- Failure-free survival: 154 days vs. 70 days (p=0.043)
- Day 99 complete response: 44.9% vs. 28.6% (p=0.035)
The company reported Q4 2024 revenue of $4.4M (down from $9.2M in Q4 2023) and full-year 2024 revenue of $41.1M (up from $36.1M in 2023). Net loss for 2024 improved to $8.1M compared to $13.3M in 2023. Cash position stands at $22.6M, expected to fund operations into Q3 2025. FDA feedback on Breakthrough Therapy designation is expected in May 2025.
Equillium (NASDAQ: EQ) announced positive topline results from its Phase 2 study of itolizumab in treating moderate to severe ulcerative colitis (UC). The study involved 90 biologic-naïve patients randomized 1:1:1 to receive itolizumab, placebo, or adalimumab.
Key findings after 12 weeks of treatment include:
- Clinical remission rate: 23.3% for itolizumab vs 20.0% for adalimumab and 10.0% for placebo
- Clinical response rate: 63.3% for itolizumab vs 60.0% for adalimumab and 46.7% for placebo
- Endoscopic remission: 16.7% for both itolizumab and adalimumab vs 6.7% for placebo
The drug was generally well tolerated, showing comparable efficacy to adalimumab, despite having more severe patients in the itolizumab arm at baseline. Additional data is expected to be presented at a scientific conference during 2025.
Equillium (EQ) reported Q3 2024 financial results, highlighting revenue of $12.2 million, up from $8.9 million in Q3 2023. The company retained rights to itolizumab following the end of Ono Pharmaceutical partnership. R&D expenses increased to $9.6 million from $9.0 million year-over-year, while G&A expenses decreased to $3.3 million. Net loss improved significantly to $7,000 compared to $3.7 million in Q3 2023. Cash position stands at $25.9 million, expected to fund operations into Q4 2025. The company is evaluating accelerating its Phase 3 EQUATOR study in aGVHD with topline data expected in Q1 2025, alongside Phase 2 ulcerative colitis study results.
Equillium (Nasdaq: EQ) has announced its participation in the upcoming Stifel Healthcare Conference in New York on November 18-19, 2024. The company will present on Tuesday, November 19 at 12:40 PM ET, highlighting its clinical programs, including the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) and the Phase 2 study of itolizumab in ulcerative colitis. The presentation will be held at the Lotte New York Palace Hotel, with management available for one-on-one meetings. A webcast will be accessible through the company's website with a 90-day replay available.
Equillium (Nasdaq: EQ) presented research findings at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, highlighting the synergistic effects of IL-15 and IL-21 on immune cell responses. The research demonstrated that these cytokines together enhance NK and CD8+ T cell activity, boost cytolytic function, and partially rescue exhausted T cells. The study showed increased production of granzyme A, granzyme B and perforin, indicating important roles in immune cell activation and survival. Dr. Stephen Connelly, chief scientific officer, emphasized the importance of targeting both cytokines in a single agent for treating inflammatory diseases or enhancing anti-tumor responses.
Equillium announced that Ono Pharmaceutical has allowed its option to acquire rights to itolizumab to expire, with Equillium maintaining all commercial rights. The decision was strategic and unrelated to clinical data. Equillium is evaluating accelerating completion of the Phase 3 EQUATOR study in aGVHD to Q1 2025. The company has enrolled over 150 patients and is temporarily pausing enrollment to review clinical options. A Phase 2 ulcerative colitis study was recently completed with topline data expected in Q1 2025. The company believes it has sufficient cash to achieve these milestones and extend operations into Q4 2025.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
